Drugnews|藥時事

Market Radar

資本市場雷達

把最新文章重新整理成投資人最常追蹤的市場訊號:BD、估值、臨床催化、CMC、GLP-1、腫瘤精準治療、AI 製藥與製藥巨頭策略。

腫瘤精準治療

9 篇
2026-11-21 · 醫學大會 Kelun's TROP2 ADC wins on survival in late-line gastric cancer: the China-made asset Merck keeps cashing

Merck's TroFuse-015 met its overall-survival endpoint in previously treated gastroesophageal adenocarcinoma. The progression-free survival endpoint was not met.

ADCTROP2gastric canceroncologylicensing
2026-11-21 · 商業分析 默沙東首付 4,700 萬美元的 ADC,胃癌又贏一次

默沙東向科倫博泰取得大中華區以外的開發與商業化權利。這次胃食道腺癌全球三期達到總生存期主要終點,無惡化存活期未達標。原始協議和後續年報揭露了簽約款及已收到的臨床里程碑款。

ADCTROP2胃癌腫瘤授權
2026-11-18 · 商業分析 Unmet Needs in MSS Colorectal Cancer and the Potential Role of HDAC Inhibition

On October 19, 2026, the U.S. FDA granted accelerated approval to GSK's Jemperli (dostarlimab), based on AZUR-1 data, for adults with stage II/III locally advanced rectal cancer with deficient mismatch repair or high microsatellite instability (dMMR/MSI-H). Patients receive immunotherapy first. Those who achieve a clinical complete response may, after evaluation, be managed nonoperatively under close surveillance, potentially avoiding surgery and radiation while preserving the rectum. [1]

HDACABT-301MSScolorectal cancer
2026-11-18 · 商業分析 MSS大腸癌的未滿足需求 HDAC路線能補上哪一塊

2026 年 10 月 19 日,美國 FDA 加速核准 GSK 的 Jemperli(dostarlimab),依據 AZUR-1 資料,用於成人第 II/III 期錯配修復缺陷/微衛星高度不穩定(dMMR/MSI-H)的局部晚期直腸癌。病人先接受免疫治療,若達到臨床完全反應,經評估後可在密切追蹤下採取非手術管理,有機會不開刀、不放療,保住直腸。[1]

HDACABT-301MSScolorectal cancer
2026-11-11 · 製藥巨頭 諾華天價基因藥爆腫瘤,傷最重的是大童市場

諾華證實 Zolgensma 上市以來收到九例腫瘤通報,兩例找到載體嵌入致癌基因 GLI1,FDA 被報導已展開調查並延伸到 Itvisma。嬰兒版會留下並加追蹤;被重算的是諾華靠 Itvisma 打開的大童與成人市場。

諾華Zolgensma基因療法SMAItvisma
2026-11-10 · 商業分析 Asia's Protein Degraders After First PROTAC

BeOne said on November 5 that its BTK degrader tacabrutideg met a pivotal Phase 2 goal, with a filing planned for mid-2027, while Veppanu, the first approved PROTAC, earned Arvinas only $0.5 million in Q3 2026 royalties. Astellas has a KRAS G12D degrader in Phase 3, and Taiwan's AnHorn is pursuing a topical AR degrader for hair loss.

protein degraderPROTACVeppanutacabrutidegsetidegrasib

GLP-1 與代謝賽道

7 篇
2026-11-20 · 商業分析 減重17.7%,恆瑞還要過全球試驗

Ribupatide中國三期48週平均減重17.7%,安慰劑1.4%。四試驗的週數與人群不同;三計畫60.35億美元名目上限中,已付首款與技轉費1.10億美元。

減重ribupatide恆瑞KaileraGLP-1
2026-11-16 · 商業分析 The $190 Billion Business Beyond Weight-Loss Drugs: Abdominal Fat Reduction Still Has No Approved Drug

The Last Mile After Weight Loss

GLP-1CBL-514Body Economy
2026-11-16 · 商業分析 瘦瘦針之後的1,900億生意:腹部減脂仍沒有核准藥

減肥之後的最後一哩路

GLP-1CBL-514Body Economy
2026-11-14 · 商業分析 FDA adds a vision-loss warning to every GLP-1

On Nov 9 FDA required NAION warnings on all GLP-1 labels, including Mounjaro and the Foundayo pill. Taiwan had labeled only semaglutide and began a class review on Nov 10. We unpack the 1.7x ratio, the lawsuits and Taiwan's next step.

GLP-1NAIONdrug safetyMounjaroTaiwan FDA
2026-11-14 · 商業分析 瘦瘦針全加失明警語,猛健樂台灣仿單是下一個

FDA 11 月 9 日要求所有 GLP-1 仿單加註罕見視神經病變 NAION,連猛健樂與口服 Foundayo 都在內;台灣只先處理 semaglutide,食藥署 11 月 10 日啟動再評估。我們拆解 1.7 倍風險的分母、官司與台灣仿單的下一步。

瘦瘦針GLP-1藥物安全猛健樂食藥署
2026-11-13 · 醫學大會 Weight-loss shots stop short of cirrhosis, so Novo bought a $4.7B fix

AASLD 2026 data show GLP-1s resolve MASH far more than they reverse fibrosis. Novo's Akero CVR and Roche's 89bio CVR both hinge on cirrhosis, while Rezdiffra grew 50% with up to 53% GLP-1 co-use.

MASHcirrhosisFGF21Novo NordiskAASLD 2026

臨床與法規催化

9 篇
2026-11-19 · 商業分析 康方被FDA退件,輝瑞搶先押注「活更久」

兩項全球一線NSCLC研究以OS終點地位作比較;交易金額與台灣關聯不代表可比療效或核准領先。

肺癌PD-1×VEGFPfizerBioNTech臨床試驗
2026-11-17 · 商業分析 FDA Rejects Akeso's Bispecific: PFS Was Not Enough

On November 15, 2026, Summit announced an FDA complete response letter for ivonescimab. The HARMONi primary OS analysis yielded p=0.057, missing the prespecified 0.0448 threshold.

AkesoSummit TherapeuticsivonescimabFDAPD-(L)1×VEGF
2026-11-17 · 商業分析 康方雙抗闖美被退,FDA只認活多久

Summit於2026年11月15日公告收到ivonescimab完整回覆函;HARMONi主要OS分析p值0.057,未達0.0448的門檻。

AkesoSummit TherapeuticsivonescimabFDAPD-(L)1×VEGF
2026-11-12 · 製藥巨頭 Bayer's First-in-Class Stroke Drug Won China First. Its Lead Over BMS Is About a Year

FDA approved Bayer's Sunharbo on Nov 9, two weeks after China. It cut ischemic stroke 26% without a significant rise in major bleeding and lists at $748.50 a month. BMS and J&J report milvexian stroke data by end-2026.

strokeBayerFactor XIanticoagulationBristol Myers Squibb
2026-11-12 · 製藥巨頭 中風新藥先在中國上市,拜耳只剩一年領先

FDA 11 月 9 日核准拜耳 Sunharbo,首個 Factor XIa 抑制劑;中國 10 月 26 日先批。三期試驗再中風降 26%、大出血無顯著增加,美國月價 748.5 美元。必治妥與嬌生的 milvexian 中風數據年底前公布。

中風拜耳Factor XI抗凝血必治妥
2026-11-11 · 製藥巨頭 Zolgensma tumors put Novartis's older-patient SMA growth at risk

Novartis confirmed nine tumor reports after Zolgensma, two with vector DNA near the GLI1 oncogene; the FDA reportedly extends the risk to Itvisma. Infant use stays; the older-patient market gets repriced.

NovartisZolgensmaGene therapySMAItvisma

BD / 授權與併購

5 篇
2026-11-15 · 商業分析 OBI–Novartis: Inside the ADC License

The OBI–Novartis ADC agreement separates a $30m upfront from conditional milestones, with exclusivity defined by selected payload classes and key funding and retained-rights terms undisclosed.

浩鼎諾華ADC平台授權
2026-11-15 · 商業分析 浩鼎授權諾華,ADC合約拆解

浩鼎與諾華的平台合作約定3,000萬美元簽約金,總潛在價值逾20億美元;拆解酬載排他範圍、條件款、研究分工與未揭露條款。

浩鼎諾華ADC平台授權
2026-11-09 · 商業分析 Boehringer Paid China $358M, Taiwan Got $10M

Boehringer Ingelheim paid SBP Group $358M upfront for six preclinical ADC and T-cell engager programs (up to ~$7.36B). Taiwan's nine 2026 out-licensing deals disclosed one upfront, $10M. The gap has two layers: what Taiwan sells, and how much human data it has.

licensing dealsBoehringer IngelheimSino BiopharmADCTaiwan biotech
2026-11-09 · 商業分析 百靈佳73.6億美元押中國新藥,台灣先輸在賣什麼

百靈佳殷格翰 11 月 4 日向中國生物製藥買下 6 個臨床前 ADC 與 T 細胞接合器,帳面最高約 73.6 億美元、首付 3.58 億美元;台灣 2026 年 9 筆對外授權公開總額約 8.3 億美元,唯一公開首付 1,000 萬美元。差距有兩層:台灣賣的多是改良型新藥、生物相似藥與單一國家權利;就算是新一代平台,韓國首付仍只有中國同類案的約九分之一,買方付錢買的是臨床數據規模。

授權交易百靈佳殷格翰中國生物製藥ADC台灣生技
2026-11-05 · 商業分析 TAHO Doubles in Two Weeks, but a Court Holds Its US Clock

TAHO (6467) closed at NT$246 on Nov 3, 2026, up 133% from its NT$105.6 IPO price on Japanese royalty news. A BMS-Pfizer patent suit in Delaware can stay final FDA approval of BEQIA for up to 30 months, Medicare's negotiated Eliquis price already fell 56% in 2026, and settled generics enter from April 1, 2028: BEQIA's US value depends on when, and at what price, it can launch.

泰合BEQIAEliquis505(b)(2)專利訴訟

AI 製藥與新技術

2 篇